IN a triumph for good sense, the National Institute for Health and Care Excellence (NICE) will not recommend medical cannabis for epilepsy and chronic pain.
Draft guidance just published says patients with chronic pain should not be offered tetrahydrocannabinol (THC) or mixtures of cannabidiol and THC unless the treatment is part of a clinical trial.
NICE has said it is currently unable to recommend cannabis-based medical products (CBMPs) for severe treatment-resistant epilepsy.
We have long since warned against the perils of legalising so-called medicinal cannabis, arguing that the evidence for its efficacy and safety is just not there, and furthermore that it is wrong that the isolated and extremely difficult cases of childhood epilepsy (which have been taken up by the legalising lobby and so receive massive media attention) should be used to overturn our world-class pharmaceutical testing and safety regulatory system.
In its draft guidance on the use of CBMPs, NICE has backed the Chief Medical Officer’s reservations we reported last March, saying that more research into the use of CBMPs for the treatment of a number of conditions was needed because ‘current research is limited and of low quality’, adding that clinical trials had shown a high level of adverse events.
You can read the report here.